Healthcare
Live Price
Offline$13.29
+1.06% today
1Y Change
-14.11%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Dr. Reddy's Laboratories Limited (RDY) is a Healthcare stock with a market cap of $1.10T and listed on NYSE. The stock last traded around $13.29 and down 14.1% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +16.6%, EPS growth of +1.6%, a dividend yield of 1.2%. What stands out right now is revenue +16.6%, EPS +1.6%, free cash flow -33.2% with operating margin 19.3% and ROIC 11.2%. The dividend is present but secondary, with a yield around 1.2%. Valuation is more restrained than many high-expectation growth names at P/E 19.5 and price/sales 3.2. Stock Foundry combines RDY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RDY Max Drawdown
-20.08%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RDY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.6B
-98.8% YoY
FY Net Income
$232.2M
-99.0% YoY
Free Cash Flow
$23.1B
+155.5% YoY
Revenue Growth
+16.6%
EPS Growth
+1.6%
Gross Margin
55.2%
Net Margin
16.4%
Income statement
INR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 325.5B | 279.2B | 245.9B | 214.4B | 2.6B |
| Gross Profit | 190.4B | 163.6B | 139.3B | 113.8B | 1.3B |
| Operating Income | 71.8B | 67.7B | 57.1B | 29.5B | 431M |
| EBITDA | 96.7B | 88.4B | 74.4B | 45.1B | 535M |
| Net Income | 56.5B | 55.7B | 45.1B | 23.6B | 232M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
INR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14.7B | 7.1B | 5.8B | 14.9B | 203M |
| Total Assets | 493.0B | 387.5B | 321.9B | 292.8B | 3.6B |
| Total Liabilities | 155.8B | 107.0B | 90.9B | 102.3B | 1.3B |
| Shareholder Equity | 333.4B | 280.6B | 231.0B | 190.5B | 2.4B |
| Total Debt | 46.8B | 20.0B | 13.5B | 33.8B | 415M |
| Net Debt | 32.1B | 12.9B | 7.7B | 19.0B | 212M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
35.7B
+27.0% YoY
Capital Expenditures
12.6B
+34.1% YoY
Free Cash Flow
23.1B
+155.5% YoY
Key ratios
Gross Margin
55.2%
Operating Margin
19.3%
Net Margin
16.4%
ROE
16.0%
Debt / Equity
0.21x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.